Please assess the completion status of the following clinical trial:

Trial Title: Determination of Analgesic Equipotent Doses of Inhaled Metoxyflurane vs. Intravenous Fentanyl

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy volunteers~2. Age 18 - 64~3. Both sex~4. No chronic disease~5. No regular medication~6. Recruited from the general population~7. Signed informed consent and expected cooperation of the subjects for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations~Exclusion Criteria:~1. Use of pain medication the last 2 days before a session~2. Use of complementary medicine the last 2 days before a session~3. Use of regular medication~4. Previous substance abuse~5. Pregnancy~6. Know allergies or serious side effects to opioids or metoxyflurane~7. Use of alcohol last 24 h before each session~8. Exclusion criteria with respect to fentanyl:~9. Hypersensitivity opposite the active substance (fentanyl) or other opioids~10. Hypersensitivity opposite the excipients (to fentanyl): sodiumclorid, water for injection, hydrochloric acid or sodium hydroxide~11. Respiratory depression without artificial ventilation~12. Use of MAO-inhibitor or use of MAO-inhibitor by two weeks before inclusion~13. Elevated intracranial pressure or brain trauma~14. Hypovolemia or hypotension~15. Myasthenia gravis~16. Exclusion criteria with respect to metoxyflurane:~17. Use metoxyflurane as anesthetic~18. Hypersensitivity opposite metoxyflurane or fluorinated anesthetics~19. Hypersensitivity opposite the excipient (to metoxyflurane):~    Butylhydroksytoulen~20. Malignant hyperthermia or persons with suspect genetic predisposition for malignant hyperthermia~21. History (to the volunteer or family) of serious adverse effects after administration of inhalation anesthetics~22. Volunteers showing sign of liver damage after use of metoxyflurane or halogenated anesthetics~23. History of liver disease~24. Clinical significant reduced kidney function or history of kidney disease~25. Changed of level of consciousness of any cause, including brain trauma, drugs or alcohol~26. Clinical detected cardiovascular unstability~27. Clinical detected respiratory depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Methoxyflurane (M) (Type: ACTIVE_COMPARATOR): A session starts with a CPT - cold pressor test (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale metoxyflurane through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second.
- Fentanyl (F1) (Type: ACTIVE_COMPARATOR): A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.025 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs.Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second.
- Fentanyl (F2) (Type: ACTIVE_COMPARATOR): A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of fentanyl 0.05 mg intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second.
- NaCl (C) (Type: PLACEBO_COMPARATOR): A session starts with a CPT (time -15 minutes). Then a 10 minutes rest before the subject receives a syringe of NaCl intravenous (time -5 minutes). At the same time the subject begin to inhale NaCl through the inhalator. The subject should first take 10 breath through the inhalator. This will take approximately 1-1.5 minutes. The subject then take a break, and then inhale the rest of the dosage before time zero.~At time zero a new CPT will be performed. At time 15 minutes the last CPT will be performed.~The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs. Each test lasts up to 90 seconds and endpoints are NRS scores every 10 second.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete